MX353589B - Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina. - Google Patents

Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.

Info

Publication number
MX353589B
MX353589B MX2013014935A MX2013014935A MX353589B MX 353589 B MX353589 B MX 353589B MX 2013014935 A MX2013014935 A MX 2013014935A MX 2013014935 A MX2013014935 A MX 2013014935A MX 353589 B MX353589 B MX 353589B
Authority
MX
Mexico
Prior art keywords
antibody
purine analog
combination therapy
purine
analog
Prior art date
Application number
MX2013014935A
Other languages
English (en)
Spanish (es)
Other versions
MX2013014935A (es
Inventor
Rojkjaer Lisa
Winderlich Mark
Steidl Stefan
Krohn Susanne
Amersdorffer Jutta
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2013014935A publication Critical patent/MX2013014935A/es
Publication of MX353589B publication Critical patent/MX353589B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MX2013014935A 2011-08-16 2012-08-14 Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina. MX353589B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161523862P 2011-08-16 2011-08-16
EP11177660 2011-08-16
PCT/EP2012/065904 WO2013024095A1 (en) 2011-08-16 2012-08-14 Combination therapy with an anti - cd19 antibody and a purine analog

Publications (2)

Publication Number Publication Date
MX2013014935A MX2013014935A (es) 2014-07-09
MX353589B true MX353589B (es) 2018-01-19

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014935A MX353589B (es) 2011-08-16 2012-08-14 Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.

Country Status (25)

Country Link
US (3) US20140227277A1 (OSRAM)
EP (2) EP2744826B1 (OSRAM)
JP (1) JP6114273B2 (OSRAM)
KR (3) KR20140071368A (OSRAM)
CN (1) CN103703027B (OSRAM)
AU (1) AU2012296905B2 (OSRAM)
BR (1) BR112013033916B1 (OSRAM)
CA (1) CA2841738C (OSRAM)
CY (1) CY1125148T1 (OSRAM)
DK (1) DK2744826T3 (OSRAM)
ES (1) ES2909720T3 (OSRAM)
HR (1) HRP20220224T1 (OSRAM)
HU (1) HUE058855T2 (OSRAM)
IL (1) IL230295B (OSRAM)
LT (1) LT2744826T (OSRAM)
MX (1) MX353589B (OSRAM)
PL (1) PL2744826T3 (OSRAM)
PT (1) PT2744826T (OSRAM)
RS (1) RS63121B1 (OSRAM)
RU (1) RU2664462C9 (OSRAM)
SG (1) SG10201606788VA (OSRAM)
SI (1) SI2744826T1 (OSRAM)
SM (1) SMT202200160T1 (OSRAM)
WO (1) WO2013024095A1 (OSRAM)
ZA (1) ZA201401835B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
CN106794231A (zh) * 2014-06-16 2017-05-31 赞科股份有限公司 用于慢性淋巴细胞性白血病(cll)的治疗
HUE046328T2 (hu) 2015-05-26 2020-03-30 Morphosys Ag CD19 elleni ellenanyag és Bruton-féle tirozin-kináz gátlójának kombinációja és a kombináció alkalmazásai
AU2016311136B2 (en) * 2015-08-21 2022-02-17 Incyte Corporation Combinations and uses thereof
PT3916392T (pt) * 2016-05-30 2024-06-04 Incyte Corp Métodos para prever o benefício terapêutico da terapia anti-cd19 nos pacientes
LT3532098T (lt) * 2016-10-28 2021-06-25 Morphosys Ag Anti cd19 antikūno derinys su bcl-2 inhibitoriumi, ir jo naudojimas
WO2018220040A1 (en) 2017-05-31 2018-12-06 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
JP7279011B2 (ja) 2017-07-10 2023-05-22 インターナショナル-ドラッグ-ディベロップメント-バイオテック 抗cd20抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗cd19抗体を用いるb細胞悪性の治療
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
KR20240131370A (ko) * 2021-12-22 2024-08-30 인사이트 코포레이션 항-cd19 항체 요법을 위한 치료 패러다임
WO2025012080A1 (en) 2023-07-13 2025-01-16 Christian-Albrechts-Universität Zu Kiel Humanized anti-cd7 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US11852A (en) 1854-10-31 Abraham bassford
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
KR101063278B1 (ko) * 1998-08-11 2011-09-07 바이오겐 아이덱 인크. B-세포 림프종을 치료하기 위한 항-cd20 항체를 포함하는 약제
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
JP2004508420A (ja) 2000-09-18 2004-03-18 アイデック ファーマスーティカルズ コーポレイション B細胞枯渇抗体/免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
ATE395413T1 (de) 2001-12-03 2008-05-15 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗cd19抗体
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
US20070136826A1 (en) * 2005-12-02 2007-06-14 Biogen Idec Inc. Anti-mouse CD20 antibodies and uses thereof
PT1966245E (pt) 2005-12-30 2011-08-31 Merck Patent Gmbh Anticorpos anti-cd19 com imunogenicidade reduzida
RS53263B (sr) * 2006-08-14 2014-08-29 Xencor Inc. Optimizovana antitela usmerena na cd19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
LT2176298T (lt) 2007-05-30 2018-04-10 Xencor, Inc. Būdai ir kompozicijos, skirti cd32b ekspresuojančių ląstelių slopinimui
SI2211904T1 (sl) 2007-10-19 2016-12-30 Seattle Genetics, Inc. CD19 vezavna sredstva in njihove uporabe
WO2010095031A2 (en) 2009-02-23 2010-08-26 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
US20120128586A1 (en) 2009-06-24 2012-05-24 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
KR20120054069A (ko) * 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 cd20 항체의 복합 요법
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
JP2013510180A (ja) * 2009-11-06 2013-03-21 インフィニティ ファーマスーティカルズ、インク. ヘッジホッグ経路阻害剤の経口製剤

Also Published As

Publication number Publication date
PT2744826T (pt) 2022-05-19
RS63121B1 (sr) 2022-05-31
EP4083071A2 (en) 2022-11-02
KR20200060779A (ko) 2020-06-01
AU2012296905B2 (en) 2017-01-05
US20240424012A1 (en) 2024-12-26
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
DK2744826T3 (da) 2022-03-28
HRP20220224T1 (hr) 2022-04-29
US20200352975A1 (en) 2020-11-12
CN103703027A (zh) 2014-04-02
RU2014103490A (ru) 2015-09-27
KR20140071368A (ko) 2014-06-11
JP6114273B2 (ja) 2017-04-12
ES2909720T3 (es) 2022-05-10
IL230295B (en) 2018-03-29
BR112013033916B1 (pt) 2022-11-16
EP2744826B1 (en) 2022-02-09
RU2664462C2 (ru) 2018-08-17
KR102117202B1 (ko) 2020-06-01
SI2744826T1 (sl) 2022-05-31
EP4083071A3 (en) 2023-02-22
CN103703027B (zh) 2018-01-12
CA2841738A1 (en) 2013-02-21
RU2664462C9 (ru) 2018-09-28
BR112013033916A2 (pt) 2017-11-28
LT2744826T (lt) 2022-04-25
CA2841738C (en) 2022-12-06
SMT202200160T1 (it) 2022-05-12
KR20190094478A (ko) 2019-08-13
US20140227277A1 (en) 2014-08-14
EP2744826A1 (en) 2014-06-25
HUE058855T2 (hu) 2022-09-28
ZA201401835B (en) 2015-06-24
PL2744826T3 (pl) 2022-05-30
CY1125148T1 (el) 2024-12-13
JP2014525925A (ja) 2014-10-02
WO2013024095A1 (en) 2013-02-21
NZ617771A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
MX353589B (es) Terapia de combinacion con un anticuerpo anti-cd19 y un analogo de purina.
MX354479B (es) Terapia de combinación con un anticuerpo anti-cd19 y una mostaza de nitrógeno.
EP3054954A4 (en) Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
CA143819S (en) Intravenous line organizer
CA144920S (en) Bottle
EP3054953A4 (en) Hdac inhibitors, alone or in combination with pi3k inhibitors, for treating non-hodgkin's lymphoma
CA141065S (en) Dual c clip
WO2014138429A3 (en) Peptidomimetic macrocycles and use thereof in regulating hif1alpha
CA141284S (en) Bracket
CA144349S (en) Chair side member
CA3019531A1 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
CA143991S (en) Dual function wine device
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
BR112017005314A2 (pt) inibidores de ssao derivados de imidazo[4,5-c]piridina
TN2013000472A1 (en) Induction of immune tolerance by using methotrexate
MX2022016270A (es) Combinacion de anticuerpo anti cd19 con un inhibidor de bcl-2 y usos de la misma.
CA141066S (en) Dual c clip
MX2022006154A (es) Combinaciones y sus usos.
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
GB201208362D0 (en) Fixing system
MX2014010940A (es) El uso de antitrombina en el tratamiento de preeclampsia.
CA141929S (en) Retainer for railings
GB2594662B (en) Absorbent articles with curved elasticized laminates
UA70775U (ru) Способ лечения менингококцемии у детей
GB2594220B (en) Absorbent articles with curved elasticized laminates

Legal Events

Date Code Title Description
FG Grant or registration